Benefit of using composite nanoparticle formulation in patients with infected wounds compared to standard wound management
Phase 4
- Conditions
- Health Condition 1: L00-L08- Infections of the skin and subcutaneous tissueHealth Condition 2: L089- Local infection of the skin and subcutaneous tissue, unspecifiedHealth Condition 3: L768- Other intraoperative and postprocedural complications of skin and subcutaneous tissue
- Registration Number
- CTRI/2022/03/041120
- Lead Sponsor
- Kalinga Institute of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Male or female patients aged more than 18 years of age
2. Patients admitted with infected wound with swab/pus/tissue culture positive for a bacteria
3. Wound of any type and any area (body part) including either post-surgery, trauma, burn or chronic underlying illness like diabetes
4.Willingness to comply with study instructions for its duration as indicated by written informed consent from the patient
Exclusion Criteria
1. Pregnant or breastfeeding women,
2. The wound with underlying cancer
3. Patients with underlying immunocompromised status (infected with HIV, any immunodeficiency)
4. Patient is sick enough requiring life support or vasopressors.
5.Participation in any clinical study, which may interfere with the current study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method